Alyftrek
What Alyftrek is used for
Alyftrek tablets are indicated for the treatment of cystic fibrosis (CF) in people aged 6 years and older who have at least one non-Class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene (see sections 4.2 and 5.1).
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Alyftrek
- Active substance
- deutivacaftor / tezacaftor / vanzacaftor
- Disease area
- Cystic Fibrosis
- Medicine group
- Other respiratory system products
- ATC code
- R07AX33
- Marketing authorisation holder
- Vertex Pharmaceuticals (Ireland) Limited
- Authorised in the EU since
- 2025
Official information
In the USA
Same active substance: Alyftrek
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Alyftrek used for?
Alyftrek tablets are indicated for the treatment of cystic fibrosis (CF) in people aged 6 years and older who have at least one non-Class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene (see sections 4.2 and 5.1).
What is the active substance in Alyftrek?
Alyftrek contains deutivacaftor / tezacaftor / vanzacaftor.
Who makes Alyftrek?
The EU marketing authorisation holder is Vertex Pharmaceuticals (Ireland) Limited.
Is Alyftrek an orphan medicine?
Yes. Alyftrek is designated an orphan medicine in the EU, for a rare disease (Cystic Fibrosis).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU